Sensitivity Sample | Outcome | Interventiona | Placebo controla | Adjusted estimateb (95% CI) | P-value |
---|---|---|---|---|---|
Eligible and participating samplec | Excessive total GWG | 47.6% (1.7%) | 45.9% (2.4%) | 1.10 (0.98, 1.22) | 0.09 |
Excessive weekly GWG | 66.8% (1.6%) | 68.9% (2.3%) | 0.99 (0.93, 1.07) | 0.85 | |
Complete case sampled | Excessive total GWG | 47.0% | 45.1% | 1.11 (1.00, 1.24) | 0.06 |
Excessive weekly GWG | 67.0% | 68.4% | 1.01 (0.94, 1.08) | 0.85 | |
Per-protocol samplee | Excessive total GWG | 45.5% (2.3%) | 41.6% (3.6%) | 1.14 (0.96, 1.37) | 0.14 |
Excessive weekly GWG | 64.2% (2.2%) | 62.2% (3.7%) | 1.07 (0.95, 1.20) | 0.28 | |
As treated samplef | Excessive total GWG | 47.4% (1.8%) | 46.6% (2.2%) | 1.08 (0.97, 1.2) | 0.15 |
Excessive weekly GWG | 66.6% (1.7%) | 68.8% (2.0%) | 1.00 (0.93, 1.07) | 0.89 | |
Self-reported pre-pregnancy weightg | Excessive total GWG | 53.9% (1.9%) | 53.1% (2.4%) | 1.05 (0.96, 1.15) | 0.26 |
Excessive weekly GWG | Not applicable | Not applicable | Not applicable | Not applicable | |
Not excessive GWG at start of treatmenth | Excessive total GWG | 42.8% (2.0%) | 39.3% (2.7%) | 1.12 (0.96, 1.30) | 0.15 |
Excessive weekly GWG | 65.6% (2.0%) | 66.3% (2.6%) | 1.02 (0.93, 1.11) | 0.68 |